Xcell Biosciences
Xcell Biosciences develops the AVATAR platform, a cell therapy manufacturing technology that brings physiologically relevant tumor microenvironment (TME) control into cell therapy workflows. The platform integrates physiologic oxygen and pressure control directly into GMP workflows to train cells for the environments they face in vivo, improving potency, persistence, and predictability for solid tumor therapies. Its…
Funding snapshot
About
Xcell Biosciences develops the AVATAR platform, a cell therapy manufacturing technology that brings physiologically relevant tumor microenvironment (TME) control into cell therapy workflows. The platform integrates physiologic oxygen and pressure control directly into GMP workflows to train cells for the environments they face in vivo, improving potency, persistence, and predictability for solid tumor therapies. Its product line includes ODYSSEY for R&D and process development optimization, FOUNDRY for clinical and commercial manufacturing with closed, automated scale-up, and AI for functional evaluation using machine-learning models for rapid potency assessment. AVATAR-expanded CAR T cells demonstrate 70% greater potency under TME conditions compared to conventional methods, selectively expanding Tcm and Tscm populations associated with efficacy. Founded in 2012 and headquartered in San Francisco, California, Xcell Biosciences has raised approximately $40.9M in Series B funding from investors including Illumina, Casdin Capital, DST Global, Lightspeed Venture Partners, Viking Global Investors, and LabCorp.
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified > Precision Medicine,
Genomics > Enabling Technologies > Instrument Systems > Single Cell Genomics,
Life Sciences Platforms and Tools > Instruments > Cell Biology > Cell Analysis
Team background
College Wise > University of California (Berkeley)
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.